Homepage Top Section2

The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric disease characterised by accelerated aging.

Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer

Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins. The facility will provide a comprehensive

This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a fully human monoclonal

The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection. CT011 is designed to target Glypican-3

This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia,

The fast track and orphan drug designations have been awarded for GFH009 (highly selective CDK9 inhibitor) to treat adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and

A selective second-generation Nav1.8 inhibitor, FZ008-145 is designed to provide non-addictive pain relief. This Nav1.8 target has been clinically validated in five acute pain and one chronic pain

The treatment is indicated for use in PD patients experiencing severe motor fluctuations and hyperkinesia or dyskinesia. This marks the introduction of the first 24-hour continuous subcutaneous infusion